73 annotations
Page 4 of 4
we now expect the full year 2022 adjusted operating margin to be 24.9%
(No comment added)
Transcript
2022 Q3
1 Nov 22
The full year guidance change also incorporates $0.10 lower EPS in Q4 for the additional FX headwind in the quarter and the revised phasing of our tax rate.
(No comment added)
Transcript
2022 Q3
1 Nov 22
the $0.08 raise for the year consists of $0.54 of operational beat in Q3, partially offset by the decision to pay $180 million or $0.36 of additional one-time colleague compensation
(No comment added)
Transcript
2022 Q3
1 Nov 22
We now expect $2.8 billion of testing revenue for the year
(No comment added)
Transcript
2022 Q3
1 Nov 22
just over $600 million in the outlook for the core business, an increase of just over $200 million for COVID-19 testing revenue and a $200 million decrease to reflect the recent changes in FX rates
(No comment added)
Transcript
2022 Q3
1 Nov 22
we’re raising our adjusted EPS guidance for 2022 by $0.08 to $23.01 per share
(No comment added)
Transcript
2022 Q3
1 Nov 22
we’re raising our full year revenue guidance by $650 million to $43.8 billion
(No comment added)
Transcript
2022 Q3
1 Nov 22
we delivered $0.36 of adjusted EPS higher than included in our previous guidance.
(No comment added)
Transcript
2022 Q3
1 Nov 22
Revenue in Q3 was approximately $800 million higher than we had incorporated in our previous 2022 guidance with just over $600 million driven by another quarter of extremely strong core organic growth, just over $200 million from additional COVID-19 testing revenue, partially offset by a small additional headwind from FX.
(No comment added)
Transcript
2022 Q3
1 Nov 22
We are gaining market share.
(No comment added)
Transcript
2022 Q3
1 Nov 22
We are increasing our revenue guidance by $650 million to $43.8 billion, which would result in 12% reported revenue growth over 2021. And we are raising our 2022 adjusted EPS guidance by $0.08 to $23.01 per share. The higher outlook primarily reflects the strength of our core business and a modest impact of additional COVID-19 testing.
(No comment added)
Transcript
2022 Q3
1 Nov 22
For the third quarter, the change in gross margin was due to the same drivers as those for our adjusted operating margin. After factoring in the decision we took to accrue the additional colleague compensation that I mentioned earlier, both adjusted operating margin and adjusted gross margin came in as we had anticipated in our prior guidance.
(No comment added)
Transcript
2022 Q3
1 Nov 22
PPD. It’s just under a 400 basis point impact on margin profile. And the rest really since the change both quarter-over-quarter and year-over-year related to the mix in business in terms of testing versus other core and an element of pricing to offset inflation
(No comment added)
Transcript
2022 Q2
14 Aug 22